Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Total Neoadjuvant Therapy in Resectable Biliary Adenocarcinoma
NCT04480190Phase 1Withdrawn
- Start
- Feb 2021
- Primary completion
- Apr 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine, Cisplatin micelle injection (HA132) and fluorouracil in biliary tract cancer (BTC). Primary endpoint: Completion of all therapy at 5 years. Planned start Feb 2021; status: withdrawn.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)fluorouracil
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04480190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480190.